THB-335 is under clinical development by Third Harmonic Bio and currently in Phase I for Chronic Urticaria Or Hives. According to GlobalData, Phase I drugs for Chronic Urticaria Or Hives have an 87% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how THB-335’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
THB-335 overview
THB-335 is under development for the treatment of inflammatory diseases of the skin like chronic spontaneous urticaria, airway (asthma). It is administered through oral route. It acts by targeting tyrosine protein kinase KIT.
Third Harmonic Bio overview
Third Harmonic Bio. (Third Harmonic) operates as a clinical state company. The company develops oral kits for treating severe allergic and mast cell-driven inflammatory diseases. It offers THB001 which is an oral small-molecule KIT Inhibitor that is used for the treatment of chronic inducible urticaria and chronic spontaneous urticaria. THB001 is initially in development for the treatment of chronic urticaria, a dermatologic disease driven by mast cell activation that results in red, itchy, painful welts or hives. The inhibitor has promising drug-like properties, excellent kinome selectivity and potent mast cell depletion activity in all relevant tissue types. Third Harmonic is headquartered in Cambridge, Massachusetts, the US.
For a complete picture of THB-335’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
